Tang Capital Management LLC Has $3.24 Million Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Tang Capital Management LLC lifted its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 28.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 900,000 shares of the company's stock after purchasing an additional 200,000 shares during the period. Tang Capital Management LLC owned 1.27% of C4 Therapeutics worth $3,240,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. ProShare Advisors LLC increased its stake in shares of C4 Therapeutics by 83.1% during the fourth quarter. ProShare Advisors LLC now owns 20,283 shares of the company's stock worth $73,000 after purchasing an additional 9,204 shares during the period. Nuveen Asset Management LLC increased its stake in shares of C4 Therapeutics by 6.4% during the fourth quarter. Nuveen Asset Management LLC now owns 192,424 shares of the company's stock worth $693,000 after purchasing an additional 11,571 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in C4 Therapeutics by 497.2% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 137,360 shares of the company's stock worth $494,000 after purchasing an additional 114,360 shares in the last quarter. Millennium Management LLC raised its stake in C4 Therapeutics by 1,548.3% in the 4th quarter. Millennium Management LLC now owns 360,125 shares of the company's stock worth $1,296,000 after purchasing an additional 338,277 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in C4 Therapeutics in the 4th quarter worth about $81,000. Institutional investors own 78.81% of the company's stock.

C4 Therapeutics Trading Down 8.1%

CCCC stock traded down $0.12 during mid-day trading on Wednesday, hitting $1.36. The stock had a trading volume of 945,445 shares, compared to its average volume of 1,393,606. The firm has a fifty day simple moving average of $1.57 and a 200 day simple moving average of $3.03. The firm has a market capitalization of $96.57 million, a P/E ratio of -0.80 and a beta of 3.10. C4 Therapeutics, Inc. has a 52 week low of $1.09 and a 52 week high of $7.66.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.11. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $3.54 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. As a group, equities analysts expect that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, UBS Group upgraded shares of C4 Therapeutics to a "hold" rating in a research note on Friday, February 14th.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.